Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist

IF 3.2 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2024-11-01 DOI:10.1016/j.clinthera.2024.08.013

Guramrit Kaur B.Pharm, Zahid Ahmad Dar M.Pharm, Ankit Bajpai M.Pharm, Ranjit Singh PhD, Ranju Bansal PhD

{"title":"Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist","authors":"Guramrit Kaur B.Pharm, Zahid Ahmad Dar M.Pharm, Ankit Bajpai M.Pharm, Ranjit Singh PhD, Ranju Bansal PhD","doi":"10.1016/j.clinthera.2024.08.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>This review article summarizes the progress and latest findings related to the investigational drug candidate CT1812, which is currently in phase 2 clinical trials for Alzheimer's disease (AD). The article outlines the development of this promising molecule and provides insights into its mechanism of action as sigma-2 receptor (S2R) antagonist along with the positive outcomes of various clinical trials. Literature mentioning AD therapeutics that specifically target amyloid-beta (Aβ) oligomers is limited even though these oligomers are established as the most neurotoxic forms of the Aβ protein. This timely article highlights the potential of CT1812 as a breakthrough in AD therapeutics, providing a new avenue for addressing the neurotoxic forms of Aβ and advancing the field toward a potential cure for AD.</div></div><div><h3>Methods</h3><div>The literature includes articles searched from PubMed and Google Scholar along with a comprehensive discussion of all the clinical research trials undertaken for CT1812. The review includes 12 clinical trials; of the total citations identified, 10 have been used to support the results of published trials.</div></div><div><h3>Findings</h3><div>The positive outcomes in the multiple clinical trials conducted on CT1812 indicate the emergence of an effective and promising drug candidate for AD. The article mentions a gap in the literature regarding AD therapeutics specifically targeting Aβ oligomers, which reveals lack of established treatments addressing Aβ oligomers, making the novel approach of CT1812 noteworthy.</div></div><div><h3>Implications</h3><div>Clinical treatments available today provide symptomatic relief, however, any drug providing a potential cure for AD remains an unanswered question. S2Rs mediated oligomer binding in addition to synaptic toxicity suggest the potential usefulness of CT1812 in AD treatment. Efficacy and safety of CT1812 in further clinical trials could represent a significant advancement in the field, offering a potential treatment that goes beyond the symptomatic relief and aimed at addressing the core mechanisms associated with AD.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"46 11","pages":"Pages e21-e28"},"PeriodicalIF":3.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291824002224","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This review article summarizes the progress and latest findings related to the investigational drug candidate CT1812, which is currently in phase 2 clinical trials for Alzheimer's disease (AD). The article outlines the development of this promising molecule and provides insights into its mechanism of action as sigma-2 receptor (S2R) antagonist along with the positive outcomes of various clinical trials. Literature mentioning AD therapeutics that specifically target amyloid-beta (Aβ) oligomers is limited even though these oligomers are established as the most neurotoxic forms of the Aβ protein. This timely article highlights the potential of CT1812 as a breakthrough in AD therapeutics, providing a new avenue for addressing the neurotoxic forms of Aβ and advancing the field toward a potential cure for AD.

Methods

The literature includes articles searched from PubMed and Google Scholar along with a comprehensive discussion of all the clinical research trials undertaken for CT1812. The review includes 12 clinical trials; of the total citations identified, 10 have been used to support the results of published trials.

Findings

The positive outcomes in the multiple clinical trials conducted on CT1812 indicate the emergence of an effective and promising drug candidate for AD. The article mentions a gap in the literature regarding AD therapeutics specifically targeting Aβ oligomers, which reveals lack of established treatments addressing Aβ oligomers, making the novel approach of CT1812 noteworthy.

Implications

Clinical treatments available today provide symptomatic relief, however, any drug providing a potential cure for AD remains an unanswered question. S2Rs mediated oligomer binding in addition to synaptic toxicity suggest the potential usefulness of CT1812 in AD treatment. Efficacy and safety of CT1812 in further clinical trials could represent a significant advancement in the field, offering a potential treatment that goes beyond the symptomatic relief and aimed at addressing the core mechanisms associated with AD.

查看原文本刊更多论文

抗阿尔茨海默氏症候选药物 CT1812 的临床最新进展：Sigma-2 受体拮抗剂。

目的：这篇综述文章概述了候选药物 CT1812 的研究进展和最新发现。文章概述了这一前景广阔的分子的开发过程，并深入分析了它作为sigma-2受体（S2R）拮抗剂的作用机制以及各种临床试验的积极成果。尽管淀粉样蛋白-β（Aβ）寡聚体已被确定为神经毒性最强的Aβ蛋白形式，但提及专门针对淀粉样蛋白-β（Aβ）寡聚体的AD疗法的文献却很有限。这篇文章适时地强调了 CT1812 作为 AD 疗法突破口的潜力，为解决 Aβ 的神经毒性形式提供了一条新途径，并推动该领域向可能治愈 AD 的方向发展：文献包括从PubMed和谷歌学术搜索到的文章，以及对CT1812进行的所有临床研究试验的全面讨论。综述包括 12 项临床试验；在已确定的总引用中，有 10 项用于支持已发表的试验结果：研究结果：CT1812在多项临床试验中取得的积极成果表明，它是一种治疗AD的有效且前景广阔的候选药物。文章提到了有关专门针对Aβ寡聚体的AD治疗药物的文献空白，这表明缺乏针对Aβ寡聚体的成熟治疗方法，因此CT1812的新方法值得关注：目前的临床治疗可缓解症状，但任何药物都有可能治愈AD，这仍是一个未解之谜。除了突触毒性外，S2Rs 介导的寡聚体结合也表明 CT1812 在治疗注意力缺失症方面具有潜在用途。CT1812在进一步临床试验中的有效性和安全性可能代表着该领域的重大进展，它提供了一种超越症状缓解的潜在治疗方法，旨在解决与AD相关的核心机制问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.